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Human, animal, and cell culture studies support the relationship between iron 
overload and lowered bone mineral density.  The hypothesis of the studies in this thesis 
was that: iron accumulates intracellularly and that this accumulation results in increased 
iron levels that alter iron-regulatory proteins and also maximally suppress osteoblast 
maturation and function.  Osteoblast-like cells isolated from fetal rat calvaria were treated 
with ferrous sulfate (FeSO4) (0-10 µM).  Intracellular iron concentration was increased 
25-fold greater than control upon 5 µM FeSO4 exposure.  Transferrin receptor and ferritin 
light-chain protein and gene expression were altered and osteoblast phenotypes were 
markedly suppressed with excessive FeSO4 treatment.   Excessive FeSO4 treatment 
resulted in high intracellular iron accumulation, alterations in key iron-regulated gene and 
protein expression, and the suppression osteoblast maturation and function in a 
concentration-dependent and time-dependent manner.  These results provide the basis for 
evaluation of mechanisms by which iron overload alters osteoblast maturation and 
function.   
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CHAPTER I 
INTRODUCTION 
 
 
 
 Iron is an essential metal that is a part of many proteins utilized by the body for 
cellular growth and survival.  Ribonucleotide reductase, the electron transport chain, and 
oxygen transportation all utilize proteins that are iron-containing (Beard 2001, Greene et 
al. 2002).  Enzymes in iron-sulfur proteins participate in reduction/oxidation (redox) 
reactions in the electron transport chain.  Aconitase, a regulatory protein, and 
ferrochelatase are non-redox enzymes that are iron-containing proteins (Arredondo et al. 
2005).  Additionally, catalases and myeloperoxidases are both iron-containing enzymes.  
Catalase is extremely important to the prevention of hydrogen peroxide (H2O2) induced 
cellular damage by converting it to water and molecular oxygen (Chiancone et al. 2004).   
 Although iron is a trace element that is pertinent to human survival, its imbalance 
can cause adverse damaging effects and these effects are seen through a multitude of 
disorders.  Iron deficiency, usually from low dietary intake of iron or excessive bleeding, 
is the most prevalent type of iron disorder in humans (Walter et al. 2002).  On the other 
extreme iron overload can result from genetic disorders, excessive iron supplementation, 
and age-related iron accumulation.  Hemochromatosis, aceruloplasminemia, and 
 
 
2 
 
Friedreich’s ataxia are some of the genetic mutations that can create iron overload in 
humans (Sheth et al. 2000).  Parenteral iron, iron via intravenous feeding, and iron 
supplementation are other examples of how iron levels in the body can accumulate 
without a physiological disposition to iron overload (Fischer et al. 2004, Blanck 2005, 
Puntarulo 2005, Besarab et al. 1999).  Dietary iron overload, from heme iron and 
fortification, in healthy humans has also been shown to contribute to iron overload (Liu et 
al. 2003, Mainous et al. 2004, Milman et al. 2003).  Iron overload, in physiological 
conditions like hemochromatosis, has been linked to decreased insulin sensitivity and 
increased risk of diabetes (Jehn et al. 2004).   
 Recently, hemochromatosis has been linked to decreased bone mineral density 
(BMD) and increased risk of osteoporosis in humans (Guggenbuhl et al. 2005, 
Anelopoulos 2006).  In vitro, osteoblast cells express the iron-regulated proteins 
transferrin receptor and ferritin throughout differentiation, suggesting that iron is 
important in osteoblast maturation and function (Gentili et al. 1994, Kasai et al. 1990, 
Spanner et al. 1995).  Initial studies in our lab have identified that excessive treatment 
doses of ferrous sulfate (FeSO4) markedly inhibits osteoblast maturation and function in 
vitro (Kilbarger et al., unpublished).  Formation of alkaline phosphatase-positive colonies 
and multi-layered mineralized nodules were markedly suppressed with excessive iron 
treatment in osteoblast-like cells isolated from fetal rat calvaria.  Additionally, genes 
characteristic of development of the osteoblast phenotype, alkaline phosphatase, bone 
sialoprotein and osteocalcin, were also dramatically suppressed.  These preliminary 
results suggest that excessive iron concentrations may inhibit development of the 
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osteoblast phenotype in vitro and consequently impair bone formation.  However, the 
extent to which intracellular iron concentration is related to osteoblast function and 
alterations in iron-regulatory proteins is unknown.  Thus, the overall hypothesis is that: 
iron accumulates intracellularly and that this accumulation results in increased iron levels 
that alter iron-regulatory proteins and also maximally suppress osteoblast maturation and 
function.  The specific aims of this project were to determine the concentration-
dependent and time-dependent relationship between excessive iron treatment and 1) 
intracellular iron concentration, 2) gene and protein expression of iron-regulatory protein, 
and 3) development of osteoblast phenotype using osteoblast like cells isolated from 
primary fetal rat calvaria.  These results provide the basis on which specific mechanisms 
of iron overload on osteoblast maturation and function can be evaluated.
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CHAPTER II 
REVIEW OF PERTINENT LITERATURE 
 
 
 
Bone remodeling is a sensitive balance between osteoclasts and osteoblasts.  
Osteoclasts originate from mononuclear hematopoietic precursors and become 
multinucleated cells that are responsible for bone resorption.  Osteoclasts commence 
bone turnover by dissolving mineralized bone making a lacunae.  This process then 
ceases and osteoblasts, derived from mesenchymal cells, begin rebuilding the area 
created by the osteoclasts by secreting bone matrix which is then mineralized.  Cell 
secretion of alkaline phosphatase and different noncollagenous proteins such as 
osteocalcin and bone sialoprotein are characteristic of mature osteoblast phenotypes 
(Aubin 1998, Voskaridou et al. 2004, Hinoi et al. 2006).  Additionally, osteoblasts 
express Ligand to receptor activator of NFκB (RANK-L), a key regulator of osteoclast 
activation.  Imbalances in bone deposition and resorption can result in conditions such as 
osteoporosis, osteopetrosis, and osteomalacia.  A reduction in BMD can lead to 
osteoporosis and is a result from an overproduction of osteoclast number or an 
underproduction of osteoblast number.  Osteopetrosis, excessive bone mass, is due to 
increased bone formation or decreased bone resorption (Cohen 2006).  Osteomalacia is a 
result of impaired mineralization that leads to excessive build up of osteoid tissue.  Thus, 
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metabolic bone diseases can result from imbalances in osteoblast and/or osteoclast 
production (Cohen 2006).         
Osteoblast cells express the iron-regulatory proteins transferrin receptor and 
ferritin during differentiation in vitro, suggesting a role of iron in osteoblast function 
(Gentili et al. 1994, Kasai et al. 1990, Spanner et al. 1995).  Transferrin receptor and 
ferritin are major iron-regulated proteins involved in transporting and storing iron.  After 
dietary iron is transported across enterocytes it is then bound and transported to tissues by 
serum transferrin proteins.  The iron bound transferrin can then be endocytosed by 
binding to transferrin-receptors on the cell surface.  Ferritin is an iron storage protein 
consisting of light and heavy chain elements.  Ferritin light chain is more prevalent in 
tissues that require long term storage, such as the spleen and liver.  Heavy chain ferritin 
levels are higher in tissues that require a rapid need for iron, such as the heart.  In 
osteoblasts ferritin light has been shown to be more prevalent in comparison to ferritin 
heavy (Spanner et al. 1995).  Iron regulatory proteins (IRP) regulate iron balance by 
binding to iron regulatory elements (IRE) located on mRNA sequences, resulting in the 
regulation of protein translation.  When intracellular iron concentration is low, IRPs bind 
to IREs and transferrin receptor mRNA stability and synthesis is increased.  At the same 
time the translation of ferritin mRNA into proteins is repressed.  In contrast, when 
intracellular iron concentration is high the IRPs are converted to cytosolic aconitase or 
degraded and transferrin receptor proteins are degraded and mRNA stability is decreased, 
while ferritin mRNA translation is activated (Crichton et al. 2002, Eisenstein 2000).  
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Under normal conditions these processes help to regulate intracellular iron concentration 
levels when deficient or excessive to protect cellular survival.  
Growth factors, such as insulin growth factor-1 (IGF-1), epidermal growth factor 
(EGF), and platelet-derived growth factor have been reported to regulate transferrin and 
iron uptake in human epidermoid carcinoma cells and multiple fibroblast lines.  Both 
IGF-1 and EGF increased the cycling, both endocytosis and exocytosis, of diferric 
transferrin bound transferrin receptor (Davis et al. 1986, Davis et al. 1987).  Growth 
factors were reported by Davis et al. (1986) in rat adipocytes to increase the uptake and 
accumulation of iron through transferrin receptor endocytosis.  In addition, these authors 
reported strong associations between cellular growth and transferrin receptor.  
Mahachoklertwattana et al. (2003) reported a correlation of reduced bone maturation with 
heightened iron deposits and insulin growth factor I (IGF-I).  Although these findings 
have not been reported in osteoblasts, it is possible that differentiating preosteoblasts 
could potentially be influenced by growth factors and their effects on iron uptake. 
Although iron is a trace element that is required for human survival, its imbalance 
can cause adverse damaging effects and these effects are seen through a multitude of 
disorders.  Iron deficiency, usually from low iron dietary intake or excessive bleeding, is 
the most prevalent type of iron disorder in humans (Walter et al. 2002).  On the other 
extreme iron overload can result from genetic disorders, excessive iron supplementation, 
and age-related iron accumulation.  Hemochromatosis, aceruloplasminemia, and 
Friedreich’s ataxia are some of the genetic mutations that can create iron overload in 
humans (Sheth et al. 2000).  Parenteral iron, iron via intravenous feeding, and iron 
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supplementation are other examples of how iron levels in the body can accumulate 
without a physiological disposition to iron overload (Fischer et al. 2004, Blanck 2005, 
Puntarulo 2005, Besarab et al. 1999).  Dietary iron overload, from heme iron and 
fortification, and excessive iron supplementation in healthy humans has also been shown 
to contribute to iron overload (Blanck et al. 2005, Fisher et al. 2004, Liu et al. 2003, 
Mainous et a. 2004, Milman et al. 2003).  Accumulation of stored iron, measured by 
ferritin levels, has also been shown to increase with aging (Johnson et al. 1994, Fleming 
et al. 2001).   
Iron is also a cofactor for key enzymes, such as prolyl and lysyl hydroxylases, 
involved in collagen synthesis (Ilich et al. 2000, Medeiros et al. 2004).  Collagen is the 
primary protein in the bone matrix, thus iron status may impact bone mass (Cohen 2006).  
Iron intake in post-menopausal women and serum ferritin levels in young pre-
menopausal women have also been found to have a positive correlation to BMD (Ilich et 
al. 2000, Maurer et al. 2005).  Iron deficiency in young, growing rats lowers bone mass 
and increases bone fragility, thus the skeleton is impacted by iron levels (Medeiros et al. 
2002, Medeiros et al. 2004).  Dietary iron deficient and hypotransferrinemic mice were 
reported to have lower bone mineralization in a study conducted by Malecki et al. (2000).  
Thus, iron is a requirement for normal bone mineralization.         
Iron Overload and the Skeleton 
 An association of reduced bone mass with iron overload in humans has been 
reported.  For example, osteopenia and osteoporosis have both become recognized as 
conditions that commonly occur in individuals with iron overload from genetic 
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conditions such as hemochromatosis (Weinberg et al. 2006).  Hemochromatosis has also 
been linked to lower BMD and increased risk of osteoporosis in men (Diamond et al. 
1989, Guggenbuhl et al. 2005, Angelopoulos 2006).  Guggenbuhl et al. (2005) evaluated 
BMD using dual-energy X-ray absorptiometry at the lumbar spine and femoral neck 
region in thirty-eight men, mean age of 47 years, with genetic hemochromatosis (GH). Of 
the men studied, 78.9% had osteopenia and 34.2% had osteoporosis.  These results were 
similar to another study (Sinigaglia et al. 1997) conducted on GH males that also used 
dual-energy X-ray absorptiometry.  Higher hepatic iron levels in this study were 
inversely correlated with lower femoral neck BMD.  Mahachoklertwattana et al. (2003) 
also reported decreased BMD in the lumbar spine of patients with hereditary β–
thalassemia/ hemoglobinopathy who had iron overload from blood transfusions.  These 
patients also had decreased bone matrix maturation and mineralization, determined using 
bone histomorphometry.  The authors concluded there was a correlation of reduced bone 
maturation with heightened iron deposits in bone and low serum levels of insulin growth 
factor I.  Although results of these human studies suggest an inverse correlation between 
iron overload and lower BMD, the extent that excess iron alters osteoblast or osteoclast 
development and function is unclear.       
 Some insights into cellular targets of iron overload have been reported using 
animal models.  Vernejoul et al. (1984) found that iron overloaded pigs had significantly 
low bone formation and a lower number of osteoblasts, in the presence of normal 
osteoclast function and normal bone resorption.  In the study of Matsushima et al. (2001), 
male Sprague-Dawley rats fed 50,000 ppm (5%) iron lactate had significantly lower body 
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weights compared to the control pair-fed group.  Iron lactate fed rats had significantly 
lower bone volume, trabecular number, and trabecular thickness than the pair-fed control 
group.  Bone resorption and bone formation were both higher at 4 weeks of iron lactate 
overload, along with reductions of alkaline phosphatase (30%) and inorganic 
phosphorous (14%) in comparison to 2 weeks of iron lactate overload.  Urinary calcium 
and iron levels were both significantly higher in both iron overloaded rats in comparison 
to control.  Tartrate-resistant acid phosphatase, an osteoclast resorption enzyme, was also 
stimulated by iron lactate overload.  Thus, the existing literature supports the hypothesis 
that both osteoblasts and osteoclasts may be impacted by iron overload.     
  Mechanisms by which iron overload alters the skeleton are unknown.  However, 
animal studies also showed that oxidative stress from iron overload may contribute to the 
development of metabolic bone disease.  Isomura et al. (2004) evaluated reactive oxygen 
species (ROS) and bone metabolism in postmenopausal Wistar rats with iron overload, 
induced by a high (5%) iron lactate diet.  Dietary iron overloaded postmenopausal rats 
had significantly lower body weights in comparison to controls, one postmenopausal 
control-diet group and one young control-diet group.  Serum levels of 8-hydroxy-2’-
deoxyguanosine, a marker of DNA oxidative damage, was significantly greater in dietary 
iron overloaded postmenopausal rats and young control diet rats in comparison to 
postmenopausal control diet rats, the reason for greater levels in young control rats was 
unknown.  Serum levels of glutathione peroxidase, an antioxidant released by osteoblasts 
in response to ROS, was dramatically lower in dietary iron overloaded postmenopausal 
rats in comparison to both controls.  Tumor growth factor –β (TGF-β), a cytokine found 
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to alter RANK-L, was 30-fold greater in urine and almost 2-fold greater in serum 
analysis.  TGF-β levels were found to be negatively correlated to glutathione peroxidase 
levels in iron fed rats in comparison to controls.  In another study (Liu et al. 2006), 
postmenopausal female rats were ovariectomized (OVX) to create estrogen deficiency 
inducing peri-/ postmenopausal osteoporosis and were then compared to non OVX rats.  
The OVX groups had a significantly greater level of free iron in cortical bone, 
determined by electron paramagnetic resonance spectrometry, in comparison to control 
groups.  1-N-docosyl-triethylenetetraminepentaacetic acid, a bone targeting chelator that 
has a high iron binding affinity, was given to some OVX rats for nine weeks.  The 
binding of iron by chelation resulted in less bone loss due to OVX.  Cancellous BMD 
was higher in chelator-treated rats in comparison to control OVX rats.  
Histomorphometric data showed a significantly lower cancellous bone resorption and 
trabecular separation, along with greater trabecular bone mass in chelator-treated OVX 
rats compared to non treated OVX rats.  Iron chelation reduced estrogen deficient 
induced bone loss, suggesting that high iron levels accumulated in bone may contribute to 
post-menopausal bone loss.  Thus, ROS or other chemical changes induced by iron 
accumulation contribute to bone loss. 
Oxidative Stress and the Skeleton 
Although the mechanism(s) responsible for bone loss with iron overload are 
unknown, the generation of ROS is a likely contributor.  ROS are considered a 
contributor in the development of osteoporosis, independent of iron status.  In a cross-
sectional study by Maggio et al. (2003), antioxidant levels in plasma were shown to be 
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dramatically lower in osteoporotic women in comparison to controls.  Studies have also 
reported a positive relationship between increasing dietary antioxidant intake and BMD 
(Hall et al. 1998, Leveille et al.1997).  Oxidative stress was shown to have a negative 
affect on BMD in a study by Basu et al. (2001).  This study measured BMD and 8-Iso-
PGF2α, an oxidative marker, in 48 women and 53 men with a mean age of 55.8 years.  
Lower BMD was shown to be significantly related to elevated 8-Iso-PGF2α.  The 
measurement of an inflammatory marker, 15-keto-dihydro-PGF2α, also showed negative 
effects on BMD.  Oxidative stress has been shown overall to have negative correlation to 
BMD.    
Evidence in vitro also suggests that ROS alter osteoblast function.  Arai et al. 
(2007) reported that H2O2-treated MC3T3-E1 osteoblastic had a marked decreased in 
nodule formation, differentiation, and osteogenic marker gene expression of alkaline 
phosphatase, bone sialoprotein, and runt-related transcription factor 2 in comparison to 
non-treated cells.  Hinoi et al. (2006) reported that Nrf2 transfected MC3T3-E1 
osteoblastic cells altered runt-related transcription factor 2 transcription, while also 
lowering osteoblast differentiation and alkaline phosphatase activity in comparison to 
non-transfected cells.  A further study by Bai et al. (2004) evaluated that oxidative stress 
stimulated the extracellular signal-regulated kinases and nuclear factor-κB signaling 
pathways using primary rabbit calvarial osteoblast and bone marrow stromal cells treated 
with H2O2.  This study also reported that treated cells had lower alkaline phosphatase 
staining and osteoblast colony forming units in comparison to non-treated cells.  
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Oxidative stress was reported in these studies to inhibit osteoblast function and 
maturation. 
 Cellular death, by apoptosis or necrosis, is one proposed mechanism by which 
iron imbalance or overload can damage cells and reduce proper cellular development and 
function.  Evidence exist that iron overload induces cell death by apoptosis and necrosis 
by generation of ROS (Rauen et al. 2004).  Iron is a potent pro-oxidant and its reducing 
capabilities make it an instigator for increasing ROS (Crichton et al. 2002).  High levels 
of iron or free ferrous iron can react with H2O2 initiating the Fenton reaction (Tenopoulou 
et al. 2005).  The end product of this reaction includes unstable free radicals and oxidized 
ferric iron.  Iron is a main transition metal that catalyzes the Haber Weiss reaction, a 
secondary reaction to the Fenton reaction (Puntarulo 2005, Simunek et al. 2005).  A 
superoxide radical (O
2-
) generated from the Fenton reaction reacts with H2O2, which in 
turn creates molecular oxygen and free hydroxyl radicals.  One specific hydroxyl radical 
that can be generated is ·OH which can induce oxidative damage to cell membranes, 
lipids, and even direct damage on DNA (Crichton et al. 2002).  Oxidative stress can 
initiate apoptosis or necrosis in cells depending on the concentration of free radicals, 
H2O2 at very high levels results in necrosis of cells (Hampton et al.1998).       
Doulias et al. (2003) and Tenopoulou et al. (2005) found that iron toxicity, in 
HeLa and Jurket cells, significantly reduced cell proliferation in comparison to controls.  
Increased intracellular iron, in comparison to extracellular iron, has been shown in Rauen 
et al. (2004) to have a stronger effect on cellular damage.  In this study the treatment of 
rat hepatocytes with iron, Fe(III)/8-hydroxyquinoline, induced precursor signs of 
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apoptosis and necrosis.  Most of the cellular injury from the iron treatment showed early 
signs of apoptosis, such as chromatin condensation, increased mitochondrial 
permeability, and nuclear shrinkage.  A smaller portion had swollen nuclei and blebbing 
showing the initiation of cell death by necrosis.  Barbouti et al. (2001) had similar 
findings, utilizing Jurket cells, that intracellular redox-active iron takes part in DNA 
damage along with H2O2.  Desferrioxiamine, a synthetic iron chelator, has also been 
reported to lower apoptosis and nuclear DNA damage inflicted by oxidative stress 
(Barbouti et al. 2001, Doulias et al. 2003, Kurz et al. 2004, Tenopoulou et al. 2005). 
Human, animal, and cell culture studies support the relationship between iron 
overload and lowered BMD.  In vitro and in vivo studies also suggest that one possible 
mechanism is through ROS.  However, little is known about the relationship between 
excess iron, intracellular iron accumulation in osteoblast, and osteoblast maturation and 
function.  The specific aims of this project were therefore, to determine the 
concentration-dependent and time-dependent relationship between excessive iron 
treatment and 1) intracellular iron concentration, 2) gene and protein expression of iron-
regulatory proteins, and 3) development of osteoblast phenotype using osteoblast-like 
cells isolated from primary fetal rat calvaria.  These results provide the basis on which 
specific mechanisms of iron overload on osteoblast maturation and function can be 
evaluated.      
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CHAPTER III  
THE EFFECT OF IRON OVERLOAD ON OSTEOBLAST FUNCTION IN CELL 
CULTURE  
 
 
 
Abstract 
 
 Although iron overload has a negative impact on BMD in vivo, the impact of iron 
overload on osteoblast function and maturation has not been reported.  This study 
investigates the extent that iron accumulates intracellularly in osteoblasts and if this 
accumulation is associated with altered iron-regulatory proteins and suppressed 
osteoblast maturation and functions.  Osteoblast-like cells isolated from fetal rat calvaria 
were treated with 0-10 µM ferrous sulfate (FeSO4).  Intracellular iron concentration was 
increased 25-fold greater than control with 5 µM FeSO4 exposure.  As expected, 
excessive FeSO4 treatment doses decreased both transferrin receptor gene and protein 
expression, while ferritin light-chain protein expression was increased.  Osteoblast 
function, shown by percent mineralized surface area, and osteoblast maturation, shown 
by osteocalcin, bone sialoprotein, and alkaline phosphatase gene expression, were 
markedly suppressed with excessive FeSO4 treatment doses.   Excessive FeSO4 treatment 
results in high intracellular iron accumulation, alterations in key iron-regulated gene and 
protein expression, and the suppression osteoblast maturation and function.  These results 
provide the basis for evaluation of mechanisms by which iron overload alters osteoblast 
maturation and function.   
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Introduction 
Iron is a trace element that is pertinent to human survival, and an imbalance in 
iron status may result in metabolic dysfunction.  For example, iron overload can 
contribute to conditions such as atherosclerosis, cancer, diabetes, and dementia (Liu et al. 
2006).  Iron overload may result from genetic disorders, excessive iron supplementation, 
and age-related iron accumulation.  Hemochromatosis, aceruloplasminemia, and 
Friedreich’s ataxia are some of the genetic mutations that can result in iron overload in 
humans (Sheth et al. 2000).  Dietary iron overload, from heme iron and fortification, and 
excessive iron supplementation are other examples of how iron levels in the body can 
accumulate without a physiological disposition to iron overload (Fischer et al. 2004, 
Blanck 2005, Puntarulo 2005, Besarab et al. 1999, Liu et al. 2003, Mainous et a. 2004, 
Milman et al).  Accumulation of stored iron, measured by ferritin levels, has also been 
shown to increase with aging (Johnson et al. 1994, Fleming et al. 2001). 
Osteoporosis, osteopetrosis, and osteomalacia are examples of metabolic bone 
diseases that can result from imbalances in osteoblast and/or osteoclast production or 
function (Cohen 2006).  These conditions have been reported in individuals with iron 
overload (Weinberg et al. 2006, Diamond et al. 1989, Guggenbuhl et al. 2005, 
Angelopoulos 2006).  Iron overload was inversely correlated with BMD in genetic 
disorders such as hemochromatosis (Guggenbuhl et al. 2005, Anelopoulos 2006).  
Oxidative stress from iron overload contributes to the development of metabolic bone 
disease in animal studies (Isomura et al. 2004).  Vernejoul et al. (1984) found that iron 
overloaded pigs had significantly low bone formation and a lower number of osteoblasts, 
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in the presence of normal osteoclast function and normal bone resorption.  This suggests 
that iron overload may alter osteoblast function.   
The primary goal of our study was to determine if iron accumulates intracellularly 
and how this accumulation alters iron-regulatory proteins and potentially suppresses 
osteoblast maturation and function.  To investigate these effects, we analyzed the 
concentration-dependent and time-dependent relationship between excessive iron 
treatment and 1) intracellular iron concentration, 2) gene and protein expression of iron-
regulatory proteins, and 3) the development of osteoblast phenotype using osteoblast-like 
cells isolated from primary fetal rat calvaria. 
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Methods 
Cell Culture:  Time-pregnant Sprague-Dawley rats were obtained on day 13 of 
pregnancy (Harlan, SD, Raleigh, NC) and housed at 19-20ºC with a 12h light-dark cycle.  
Rats were provided Harlan Teklad 7002 6% mouse/rat diet and water ad libitum.  Dams 
were sacrificed at day 21 of pregnancy by CO2 overdose and pups were removed.  These 
procedures were approved by the Institutional Animal Care and Use Committee 
(IACUC).   
Calvaria were aseptically removed, cleaned of residual tissue, and digested using 
five sequential collagenase digestions.  Cells were allowed to attach and incubate for 24 
hours in α-Modified Eagle’s Medium (FBS), 15% Fetal Bovine Serum, 10% antibiotics.  
Cells were trypsinized and then seeded at 3,000 cells/cm² in 6 well plates.  The cells were 
grown in osteogenic culture media, containing α-Modified Eagle’s Medium, 10% Fetal 
Bovine Serum, 10% antibiotics, 1% ascorbic acid, 1% sodium β-glycerolphosphate, and 
10
-8
 dexamethasone.  Cells were held in a 37ºC incubator with 95% air and 5% CO2.   
At confluence, approximately day 8 of culture, treatment with Iron(II) sulfate 
heptahydrate FeSO4 (Sigma, F7002-250G) (1-10 µM FeSO4) began.  Fresh media and 
FeSO4 were provided every 2-3 days.  Fresh FeSO4 stock solution was prepared each 
time by dissolving FeSO4 in deionized water and serially diluted in media before media 
changes.  Final concentrations range from 0-10 µM FeSO4.  Deionized water was utilized 
as the control (0 µM) treatment.  Iron concentration values were confirmed by Graphite 
Furnace Atomic Absorption Spectrometry (See Appendix).  The 0 µM dose contained 
0.003 µmol/L iron, due primarily to the iron contained in FBS.  Percent increase above 
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control (0 µM ) in FeSO4 treatment doses are as follows: 1 µM (32% increase), 2 µM 
(61% increase), 3 µM (86% increase), 4 µM (118% increase), and 5 µM (134% increase).  
Some studies also used a 10 µM dose, but this dose was not analyzed spectrometrically. 
Graphite Furnace Atomic Absorption Spectrometry (GFAAS):  GFAAS was used to 
measure the iron concentration in reagents and also intracellular iron concentrations using 
a protocol adapted from Erikson et al. 2006.  At the midpoint (D15) and end of culture 
(~D20 – D21), media was removed, and cells were washed twice with PBS.  Cells were 
scraped off the cell culture plate in PBS, pipeted into 1.5mL microcentrifuge tube, then 
digested in 100% Ultra Pure Nitric Acid at 60ºC for 48 hours in a sand bath in a fume 
hood.  A 1:20 dilution of digested cell lysate in ultra pure nitric acid was subjected to 
GFAAS.  Media and reagents were also digested and analyzed as described above.  
Protein concentration of cell digest was assessed by bicinchoninic acid assay (BCA) 
(Pierce, Product #23227) and normalized values are expressed as nmol Fe/ mg protein. 
Staining:  At the end of culture (~ D20 – D21), cells were stained for alkaline 
phosphatase positive colonies (deep pink), which indicates cells that have potential to 
become osteoblasts.  Cells were then counterstained with 2.5% silver nitrate (von Kossa 
stain), which stains mineralized nodules dark brown.  Plates were scanned and the 
percentage of surface that was mineralized was determined using Adobe Photoshop 
(version 6.0).     
Semi-quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR):  
Cells were scraped from wells in 1mL of TRIZOL (Invitrogen) and RNA was extracted 
using procedures specified by manufacturer.  Isolated RNA was dissolved in 20µL of 
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DEPC water and DNase treated.  RNA purity and concentration were determined 
spectrophotometrically at 260 and 280 nm using a Beckman Spectrophotometer.  1µg of 
RNA was reverse transcribed using 1µg Oligo dT and an Omniscript RT kit (Qiagen) by 
manufacturers instructions.  cDNA was then be diluted to 1:10 in nuclease-free water.  As 
a procedural control, PCR was performed on RNA not subjected to reverse transcription 
to confirm the absence of nonspecific interference.  Reagent contamination was 
controlled for by using nuclease free water in place of cDNA during the reverse 
transcription reaction.  1µL of the diluted cDNA was used in the PCR reactions using a 
Taq polymerase PCR kit (Qiagen) and primers (refer to Table 1) specific for bone 
sialoprotein, osteocalcin, transferrin receptor, alkaline phosphatase and ribosomal L32.  
Primers were designed to span exon/exon junction to control for nonspecific PCR 
products.  Each gene was optimized within the exponential phase of amplification curve.  
PCR products were separated by electrophoresis on a 1% agarose gel stained with 
ethidium bromide. Gels were visualized with ultra-violet light and net intensities 
quantified using Kodak Imaging Station.  Net intensities were normalized to the mean net 
intensity values of ribosomal L32.   
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Table 1:  RT-PCR primer information. 
 
Primer Sequence Annealing 
Temperature 
Fragment 
Size 
Ribosomal L32 
 1 F- CAT GGC TGC CCT TCGGCC TC 
R- CAT TCT CTT CGC TGC GTA GCC 
56° 403bp 
Osteocalcin 
 1 F- AGG ACC CTC TCT CTG CTC AC 
R- AAC GGT GGT GCC ATA GAT GC 
56° 274bp 
Transferrin Receptor 
 2 F- GGC CGG TCA GTT CAT TAT TA 
R- CTC ATG ACG AAT CTG TTT GTT 
55° 237bp 
Bone Sialoprotein 
 1 F- CGC CTA CTT TTA TCC TCC TCT G 
R- CTG ACC CTC GTA GCC TTC ATA G 
56° 780bp 
Alkaline Phosphatase 
 
F- GAC CTT GAA AAA TGC CCT GA 
R- CGC ATC TCA TTG TCC GAG TA 
56° 474bp 
 
1 
Bonnelye et al. 2001, 
 2
 Liu et al. 2003  
 
 
 
Western Blotting:  Proteins were collected in 150 µL of RIPA lysis buffer, containing 
protease inhibitor cocktail kit (Calbiochem, Cat. #539131), 10 mM sodium fluride, 20 
mM β-glycerol phosphate, 0.1 mM sodium orthovanadate.  Proteins were then sonicated 
on ice and centrifuged (Eppendorf 5424) at 16,000 x g for 20 minutes.  Supernatants were 
removed and stored in -80ºC freezer.  Protein concentrations were determined as 
described above.  20µg of protein was electrophoresed in NuPage 4-12% Bis-Tris gels 
(Invitrogen, Cat. NPO322BOX) and proteins were transferred for 3.5 h onto 
polyvinylidene difluoride membrane (Immobilon, Cat. IPVH00010).  The membrane was 
then blocked with 5% milk in Tris Buffer Saline with Tween-20 (TBS-T) (SigmaUltra, 
Product #P7949-500ML).  The membrane was then incubated overnight at 4°C with 
primary antibodies in 5% Bovine Albumin (Sigma, #A-9418)/ TBS-T.  Primary Abs 
include anti-β-actin (Sigma, #A-5441), anti-human transferrin receptor (Zymed, #13-
16800), anti-ferritin rabbit (Alpha Diagnostic, #FerL14A).  Secondary antibodies are 
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donkey anti-mouse IgG (Affinity Bioagents, #SA1-100) for β-actin and TrfR, and goat 
anti-rabbit IgG (Cell Signaling, #7044) for ferritin light chain.  Both secondary antibodies 
were conjugated to horseradish peroxidase and then incubated with membrane for 30 
minutes at room temperature.  The membrane was washed with TBS-T and analyzed with 
Western Lightning Chemiluminescence Reagent Plus kit (PerkinElmer, #NEL105) per 
manufacturer protocol.  ß-Actin was used as a loading control.  ReStore Western Blotting 
Stripping Buffer (Pierce, #21059) was used to strip membrane per manufacturer protocol 
and re-probed for 30 minutes with mouse anti-actin (Sigma, #A-5441) in 5% milk/ TBS-
T.  It was then washed in TBS-T and probed with horseradish peroxidase -conjugated 
donkey anti-mouse IgG (Affinity Bioagents #SA1-100).   
Statistics:  One-way analysis of variance (ANOVA) was used to determine the 
significance of differences among treatments for RT-PCR, percent surface area 
mineralization, and intracellular iron concentration levels.  A two-way ANOVA was used 
to evaluate the significance of differences in the main effects of treatment and time when 
variables were evaluated at two time points of culture.  Where the interaction was 
significant, a one-way ANOVA was conducted separately for each time point.  Statistical 
differences between treatments were determined by Tukey HSD post hoc analysis.  P < 
0.05 was considered significant.   
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Results 
The Effects of Iron Overload on Intracellular Iron 
Study 1 
 Intracellular iron concentrations increased in a dose-dependent manner at D21 of 
cell culture (Figure 1).  The intracellular iron concentration of control cells (0 µM) was 
2.56 +/- 0.02 nmol Fe/mg protein (n = 3 wells).  There was an approximately 20 times (p 
< 0.05) higher intracellular iron level at 5 µM and 10 µM FeSO4, in comparison to the 1 
µM and the control (0 µM) doses.  There were no differences in intracellular iron 
concentration levels between the 1 µM FeSO4 and the 0 µM doses.  Differences in 
intracellular iron concentrations levels with 5 µM and 10 µM FeSO4 treatments were also 
not significantly different.   
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Figure 1:  Intracellular iron concentration (% of control) in osteoblast-like cells isolated from 
fetal rat calvaria at D21 of cell culture.  Results represent the mean +/- SEM, n = 3 - 5 wells 
analyzed per treatment for intracellular iron and n = 3 wells analyzed for protein (nmol of 
Fe/mg of protein) for each treatment.  Mean differences, determined by Tukey HSD (p < 
0.05), are indicated by letters.  
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Study 2 
 Because there were no differences between the 5 µM and 10 µM FeSO4 doses the 
effect of time of culture and treatment doses lower than 5 µM FeSO4 on intracellular iron 
concentration were evaluated (Figure 2).  At D15, control cells contained 3.05 +/- 0.14 
nmol Fe/mg protein (n = 6).  Intracellular iron concentration of control cells was lower on 
D20 of culture (1.85 +/- 0.08 nmol Fe/mg protein, n = 6) than on D15.  Due to a significant 
time and treatment interaction, results for D15 and D20 were analyzed by separate one-
way ANOVA.  At D15 of cell culture, the 2 µM and 3 µM FeSO4 treatment had 
approximately 10 times higher (p < 0.05) intracellular iron levels in comparison to the 0 
µM (control) (Figure 2A).  The 4 µM and 5 µM FeSO4 doses were 25 to 30 times higher, 
respectively, than the 0 µM (control).  The 4 µM dose was approximately 25% lower (p 
< 0.05) than the 5 µM FeSO4 dose.  At D20 of cell culture intracellular iron 
concentration levels increased with increasing treatment doses of FeSO4 (Figure 2B).  
Intracellular iron concentration level was approximately 40 times higher at 5 µM FeSO4 
dose when compared to control (p < 0.05).   
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Figure 2:  Intracellular iron concentration (% of control) in osteoblast-like cells isolated 
from fetal rat calvaria on D15 and D20 of cell culture.  (A) D15 of cell culture.  (B) D20 
of cell culture.  Results represent the mean +/- SEM, n = 6 wells analyzed per treatment 
for intracellular iron and n = 6 wells analyzed for protein for each treatment.  Mean 
differences, determined by Tukey HSD (p < 0.05), within the day are indicated by letters.  
.  
 
A.  Day 15  
B.  Day 20  ----------------------FeSO4---------------------- 
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The Effects of Iron Overload on Iron-Regulatory Gene and Protein Expression 
Study 1 
Gene expression of transferrin receptor was suppressed at D21 of cell culture with 
excessive FeSO4 treatment (Figure 3).  Representative gels (Figure 3A) demonstrate that 
transferrin receptor was decreased markedly with 1 µM FeSO4 treatment.  The 5 µM and 
10 µM FeSO4 treatments had an even more pronounced suppressive affect in comparison 
to 1 µM FeSO4 and 0 µM (control) (Figure 7B). 
 
 
 
 
 
0 µM 1 µM 5 µM 10 µM
0.00
0.25
0.50
0.75
1.00
T
rf
R
/L
3
2
--------------FeSO4--------------
b
a
c
c
 
Figure 3: Transferrin receptor (TrfR) gene expression on D21 of cell culture.  (A) 
Representative gel of TrfR and ribosomal L32 gene expression.  (B) TrfR gene net intensities 
were normalized to an internal control, ribosomal L32 mRNA.  Net intensity results represent 
the mean +/- SEM of one sample, each sample ran in triplicate.  Results are representative of 
three independent studies.  Mean differences, determined by Tukey HSD (p < 0.05), are 
indicated by letters. 
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Figure 4: Transferrin receptor (TrfR) gene expression on D15 and D20 of cell culture.  (A) 
Representative gel of TrfR and ribosomal L32 gene expression.  (B) TrfR net intensities were 
normalized to an internal control, ribosomal L32 mRNA.  Net intensity results represent the mean 
+/- SEM of one sample, each sample ran in triplicate.  Mean differences, determined by Tukey 
HSD (p < 0.05), within the day are indicated by letters. 
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Study 2 
Since both 5 µM and 10 µM FeSO4 doses had maximal suppressive effects on 
TrfR, the dose-reponse relationship of lower FeSO4 concentrations was determined.  The 
effect of 1-5 µM FeSO4 treatment doses on transferrin receptor gene expression at D15 
and D20 of cell culture is presented in Figure 4.  Results indicate that at both mid-
differentiation (D15) and the late differentiation (D20), there was a significant (p < 0.05) 
main effect of treatment, but there was no significant (p < 0.05) main effect of time.  
TrfR gene expression was markedly suppressed only with the 4 µM and 5 µM FeSO4 
treatment compared to control.   
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Study 1 
Protein expression for transferrin receptor and ferritin light-chain was determined 
(Figure 5).  Transferrin receptor protein expression was suppressed with 5 µM FeSO4 and 
more markedly suppressed with 10 µM FeSO4 treatment in comparison to the 1 µM and 
control (0 µM) levels (Figure 5A).  Ferritin light chain protein expression was higher 
with the 5 µM and 10 µM FeSO4 treatment doses in comparison to the 1 µM FeSO4 and 
control (0µM) (Figure 5B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5:  Protein expression of transferrin receptor (TrfR) (A) and ferritin light chain 
(Fer-L) (B).  β-Actin was used as a loading control and determined on the same gel.   
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Study 2 
In order to further examine the time and treatment effects of FeSO4 on transferrin 
receptor and ferritin light-chain protein expression, the effects of lower FeSO4 doses at 
two times of culture were then evaluated (Figure 6).  Transferrin protein expression was 
slightly suppressed with 1 µM, 2 µM, and 3 µM FeSO4 and markedly suppressed with 4 
µM and 5 µM FeSO4 treatment in comparison to the control (0 µM) at both D15 and D20 
of cell culture.  There was little ferritin light-chain protein expression evident at D15 of 
cell culture.  Ferritin light-chain protein expression at D20 of cell culture was slightly 
higher with the 4 µM treatment and 5 µM FeSO4 treatment doses in comparison to all 
other FeSO4 treatments and control (0µM).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6:  Protein expression of transferrin receptor (TrfR) and ferritin light chain (Fer-
L) on D15 and D20 of cell culture.  All runs shown are from the same representative gel.  
TrfR is the lower band, identified with an arrow.  β-Actin was used as a loading control.  
Results are representative of two independent studies.   
D15----------------------------------------   D20--------------------------------------
β-Actin 
TrfR 
Fer-L 
   0       1       2       3       4        5       0       1        2       3       4       5    µMFeSO4 
 
 
30 
 
Effects of Iron Overload on Osteoblast Function 
 
Study 1 
 
Excessive doses of FeSO4 treatment noticeably reduced mineralized nodules and 
percent mineralized surface area at D21 of cell culture (Figure 7).  Alkaline phosphatase-
positive colonies (pink) were dramatically reduced with 5 µM and 10 µM FeSO4 and 
there were no visible mineralized nodules (brown) in wells treated with 10 µM FeSO4 
(Figure 7A).  Percent mineralized surface area was not significantly different between the 
1 µM and control (0 µM) FeSO4 (Figure 7B).  There was a significantly (p < 0.05) lower 
percent of mineralized surface area, 75% and 100% lower, respectively, with 5 µM and 
10 µM FeSO4 compared to the 1 µM and control (0 µM).  There were also significant (p 
< 0.05) differences between the 5 µM and 10 µM FeSO4 dose, the 10 µM FeSO4 dose. 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
 
 
 
 
 
0µM 1µM 5µM 10µM
0.00
5.00
10.00
15.00
20.00
%
 M
in
e
ra
li
z
e
d
  
------------------FeSO4------------------
a
b
c
a
 
Figure 7:  Mineralized nodule formation and percent mineralization of osteoblast-like cells 
isolated from fetal rat calvaria at D21 of cell culture.  (A) Representative stained wells 
showing alkaline phosphatase positive-colonies (pink) and mineralized nodules (brown).  (B) 
Percent of cell culture dish covered with mineralized nodules.  Results represent the mean +/- 
SEM, n = 3 wells per treatment from one study.  Representative results of three independent 
studies.  Mean differences, determined by Tukey HSD (p < 0.05), are indicated by letters.  
 
 
 
 
 
B 
A 
FeSO4 
 
32 
 
Study 2 
In order to further evaluate the dose-response between FeSO4 treatment and 
mineralization smaller increments in FeSO4 treatment doses were evaluated (Figure 8).  
Visually there was a slight suppression at D20 in mineralized nodule formation and 
alkaline phosphatase-positive colonies with both 2 µM and 3 µM treatments compared to 
0 µM and 1 µM treatments (Figure 8A).  In comparison, even more dramatic reductions 
were seen with the 4 µM and 5 µM FeSO4 treatment doses and there were no visible 
mineralized nodules in both compared to all treatment doses and 0 µM (control).  There 
were no significant differences in percent mineralized surface area between the 1 µM 
FeSO4 dose and 0 µM (control) (Figure 8B).  Percent mineralization was about 30% (p < 
0.05) lower for the 2 µM and 3 µM FeSO4 treatments compared to 0 µM and 1uM 
treatment doses.  Percent mineralized surface area with the 4 µM and 5uM FeSO4 doses 
were 90 to 100% lower than the control, but there was no significant difference between 
these treatment doses (p < 0.05).   
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Figure 8:  Mineralized nodule formation and percent mineralization of osteoblast-like cells 
isolated from fetal rat calvaria at D20.  (A) Representative stained wells showing alkaline 
phosphatase positive-colonies (pink) and mineralized nodules (brown).  (B) Percent of cell 
culture dish covered with mineralized nodules.  Results represent the mean +/- SEM, n = 4-10 
wells per treatment.  Mean differences, determined by Tukey HSD (p < 0.05), are indicated 
by letters.  
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The Effects of Iron Overload on Osteoblast Maturation 
Study 1 
Excessive FeSO4 treatment suppressed osteoblast phenotypic gene expression of 
alkaline phosphatase (ALP), bone sialoprotein (BSP), and osteocalcin (OCN) at D21 of 
cell culture (Figure 9).  The 5 µM and 10 µM FeSO4 treatment doses had a pronounced 
suppressive effect on all osteoblast phenotypic genes in comparison to the 0 µM (control) 
and 1 µM FeSO4 treatment doses (Figure 9A).  The osteoblast phenotypic gene expression 
of ALP, BSP, and OCN were suppressed with 5 µM and more dramatically suppressed 
with 10 µM FeSO4 when compared to the 0 µM (control) (Figure 9B).  ALP was the only 
gene suppressed with 1 µM FeSO4 treatment.   
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Figure 9:  Gene expression of alkaline phosphatase (ALP), bone sialoprotein (BSP), and 
osteocalcin (OCN) on D21 of cell culture.  (A) Representative gel presenting the gene 
expression of ALP, BSP, OCN, and ribosomal L32.  (B) ALP, BSP, and OCN net 
intensities were normalized to an internal control, ribosomal L32 mRNA.  Net intensity 
results represent the mean +/- SEM of one sample, each run in triplicate.  These results 
are representative of three independent studies.  Mean differences, determined by Tukey 
HSD (p < 0.05), are indicated by letters.  
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Study 2 
The incremental effect of FeSO4 on osteoblast phenotype at mid and late 
differentiation (D15 and D20 of cell culture) was examined.  Excessive FeSO4 treatment 
suppressed osteoblast phenotypic gene expression of alkaline phosphatase (ALP), bone 
sialoprotein (BSP), and osteocalcin (OCN) on both D15 and D20 of cell culture (Figure 
10).  ALP gene expression was not markedly altered at any FeSO4 dose at D15 or on D20 
in comparison to the control treatment (0 µM).  BSP gene expression was markedly 
suppressed with 5µM FeSO4 treatments doses at D15 and D20 in comparison to the 
control (0 µM).  OCN gene expression was dramatically suppressed with the 4 µM and 5 
µM FeSO4 treatment in comparison to all other treatments and control levels (0 µM) at 
both D15 and D20.   
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Figure 10: Gene expression of alkaline phosphatase (ALP), bone sialoprotein (BSP), and 
osteocalcin (OCN) on D15 and D20 of cell culture.  (A) Representative gel presenting the 
gene expression of ALP, BSP, OCN, and ribosomal L32.  (B) ALP, BSP, OCN net 
intensities were normalized to an internal control, ribosomal L32 mRNA.  Net intensity 
results represent the mean +/- SEM of one sample, each run in triplicate.  Mean 
differences, determined by Tukey HSD (p < 0.05), within the day are indicated by letters.  
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Discussion 
 This is the first report of iron accumulation in an osteoblast cell culture, and the 
relationship of iron overload to altered iron-regulated gene and protein expression and 
suppressed osteoblast maturation and function.  Intracellular iron concentration levels 
were shown to increase with excessive FeSO4 treatment, demonstrating iron 
accumulating ability.  The 4 µM FeSO4 treatment dose resulted in near maximal 
intracellular iron, while maximum intracellular iron levels were reached with 5 µM and 
10 µM FeSO4 treatments.  These intracellular iron changes occurred at the same FeSO4 
doses that markedly altered transferrin receptor and ferritin light chain, and suppressed 
osteoblast phenotypic maturation and function.  Thus results suggest that iron-regulatory 
proteins in osteoblasts are influenced by intracellular iron concentration during 
differentiation and that there is an inverse relationship between intracellular iron 
accumulation and osteoblast maturation and function.  These results also suggest that iron 
excess may be important to consider when assessing bone health.   
Although the effect of excessive iron treatment on intracellular iron concentration 
has not previously been reported in osteoblast-like cells, other cell systems have been 
evaluated.  A study by Hoepken et al. (2004) reported that excessive iron treatment in 
astrocytes increased intracellular iron in a time- and concentration-dependent manner.  
Although maximum levels in the study by Hoepken et al. (2004) were not reported, 
intracellular iron was reported to be 5- and 17-fold higher than the control (0 µM ).  Non-
transferrin-bound iron loading in cultured rat myocardiocytes and human hepatocytes has 
also been reported to increase intracellular iron concentration levels (Iancu et al. 1987, 
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Parkes et al. 1993, Cable et al. 1998).  Results of these previous studies are consistent 
with the current study, indicating that intracellular iron concentration increased with 
increasing FeSO4 treatment.  The excessive doses used in the current study were 
approximately 1.5-fold to 3-fold (4 µM, 5 µM, and 10 µM FeSO4 treatment) higher iron 
concentration than the control dose (0 µM).  Hemochromatotic patients have been 
reported to have serum iron levels that are 2- to 3-fold higher than normal healthy iron 
serum values (Jacobs et al. 1972, Bacon 2001).  Thus, it is conceivable that intracellular 
iron concentration in osteoblasts increase in vivo with increases in serum iron levels.  
Previous studies have reported that osteoblast-like cells isolated from chick 
embryo tibia and fetal rat calvaria, along with UMR-106-01 osteoblast-like cells, express 
the iron-regulated proteins transferrin receptor and ferritin, light and heavy chain, during 
differentiation in vitro (Gentili et al. 1994, Kasai et al. 1990, Spanner et al. 1995).  
Ferritin light chain is more prevalent in tissues that require long term storage, such as the 
spleen and liver.  Heavy chain ferritin levels are higher in tissues that require a rapid need 
for iron, such as the heart.  In osteoblasts ferritin light chain has been shown to be more 
prevalent in comparison to ferritin heavy chain (Spanner et al. 1995).  Decreased 
transferrin receptor gene and protein expression and increased ferritin light chain protein 
expression in response to excessive iron treatment has not previously been reported in 
osteoblast-like cells.  These results are consistent with the results of in vitro studies using 
hepatocytes and astrocytes, where iron overload down-regulated transferrin receptor and 
up-regulates ferritin light chain gene and protein expression (Cairo et al. 1994, Hoepken 
et al. 2004, Siah et al. 2006).   Human and animal studies on iron overload have reported 
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the same results; these in vivo studies also reported that there were no changes in ferritin 
heavy chain gene and protein expression (Pietrangelo et al. 1990, Lu et al. 1991, 
Pietrangelo et al. 1991, Pietrangelo et al. 1992, Cairo et al. 1994).   
It is well established that the immature or precursor form of transferrin receptor 
(86 kDa) go through glycosylation (93 kDa) in the endoplasmic reticulum and 
homodimers (172 kDa) are further formed by disulfide bridges.  The glycan chains 
further develop into olgliosacharides, creating mature transferrin receptor homodimers 
(190 kDa), after passing through the Golgi apparatus (Van Driel et al. 1985, Yang et al. 
1993).  These mature forms can potentially be altered through phosphorylated or fatty 
acylation (Van Driel et al. 1985, Jing et al. 1990, Beauchamp et al. 1994).  This suggests 
that the lower band or lower molecular weight band in the transferrin receptor Western 
blot analysis is representative of a less glycosylated form of transferrin receptor.  Results 
presented here would suggest that transferrin receptor is not being posttranslationally 
modified during excessive iron treatment.  The upper band or heterogeneously 
glycosylated form is increased with excessive iron treatment.  This suggests that the 
mature form of transferrin receptor has reached elevated levels, but that precursors in turn 
are being down-regulated.     
In this study, osteoblast phenotypic development and function are dramatically 
reduced in response to increasing FeSO4 treatment.  Although previous studies on the 
effects of excessive iron on osteoblast function and maturation in vitro have not been 
reported, these effects in vivo have been reported.  Animal and human studies have 
reported links between iron overload and decreased BMD, lower serum osteocalcin, 
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delays in bone mineralization, lower bone formation, and lower osteoblast number 
(Vernejoul et al. 1984, Matsushima et al. 2001, Domrongkitchaiporn et al. 2003, 
Mahachoklertwattana et al. 2003, Guggenbuhl et al. 2005, Anelopoulos 2006, Salama et 
al. 2006).   
Further studies are needed to determine potential mechanisms of iron overload 
effects on osteoblast maturation and function.  Oxidative stress and the induction of free 
radicals from labile iron, also known as “redox-active” or “chelatable”, is a likely 
contributor.  Excessive intracellular labile iron has been reported to heighten oxidative 
stress in rat hepatocytes and Jurket cells (Barbouti et al. 2001, Rauen et al. 2004).  A 
novel finding in the current study was the evaluation of increasing intracellular iron 
concentration levels with excessive FeSO4 treatment.  However, the proportion of 
intracellular iron that was free versus bound iron was not determined.  Intracellular iron 
concentration contributes to all bound or unbound iron within the cell and further analysis 
of only redox-active iron would provide a clearer insight into potential mechanisms.   
Human studies have reported that oxidative stress negatively affects BMD 
(Maggio et al. 2003, Hall et al. 1998, Leveille et al.1997, Basu et al. 2001).  Evidence in 
vitro also suggests that ROS alter osteoblast function.  Arai et al. (2007) using MC3T3-
E1 cells treated with H2O2, evaluated the effects of oxidative stress on osteoblast 
mineralization.  Nodule formation and the gene expression of alkaline phosphatase, bone 
sialoprotein, and runt-related transcription factor 2 (Runx2), a key activator of 
osteocalcin transcription, were suppressed in H2O2-treated cells when compared to non-
treated cells.  A further study by Hinoi et al. (2006) reported that Nrf2 (nuclear factor E2 
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p45-related factor 2) alters Runx2 transcription and lowers osteoblast differentiation.  
Significantly lower levels were reported in alkaline phosphatase activity and the 
osteoblast differentiation gene markers Runx2, bone sialoprotein, and osteocalcin in Nrf2 
transfected MC3T3-E1 cells in comparison to non-transfected cells.  The overexpression 
of Nrf2 was reported to significantly lower Runx2-dependent stimulation of osteocalcin 
gene 2, a mouse osteocalcin promoter.  This study, in addition with Arai et al. (2007), 
supports the role of Nrf2 on altering Runx2, ultimately resulting in lower osteoblast 
differentiation.     
Oxidative stress has been shown to play a major role in suppressing osteoblast 
differentiation by triggering extracellular signaling pathways.  Bai et al. (2004), using 
primary rabbit calvarial osteoblast and bone marrow stromal cells treated with H2O2, 
reported that oxidative stress stimulated the extracellular signal-regulated kinases (ERK) 
and nuclear factor-κB (NFκB) signaling pathways.  Treated cells had dramatically lower 
alkaline phosphatase staining, alkaline phosphatase protein expression, and osteoblast 
colony forming units in comparison to non-treated cells.  Treated cells also had dramatic 
suppression of type I collagen and inhibition of nuclear Runx2.  Bone morphogenetic 
protein-2, an initiator of Runx2 transcription, and Runx2 protein levels were not 
suppressed in treated cells compared to controls.  This study experimentally blocked 
NFκB and ERK pathways and reported a decreased suppression of nuclear Runx2 and 
type I collagen protein expression, thus confirming the involvement of these pathways in 
inhibiting osteoblast differentiation in response to oxidative stress.   
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In conclusion, this study presents novel findings that excessive FeSO4 treatment 
increased intracellular iron, altered key iron-regulated gene and protein expression, and 
suppressed osteoblast maturation and function in osteoblast-like cells isolated from fetal 
rat calvaria in a dose-dependent manner.  Findings of this study provide a basic 
foundation for further examining potential mechanisms for which iron overload affects 
the skeleton and suggests that iron excess may be important to consider when assessing 
bone health.  
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CHAPTER IV 
EPILOGUE 
 
 
 
The gene and protein expression of transferrin receptor and ferritin light chain 
were altered with excessive iron treatment.  Although these are novel findings in 
osteoblast-like cells isolated from fetal rat calvaria, further analysis of other iron-
regulated proteins will provide more insight into potential mechanisms.  For example, 
divalent metal transporter is another iron-regulated protein that has been reported to be 
involved in iron uptake by enterocytes and astrocytes (Morgan et al. 2002, Erikson et al. 
2006).  This transporter has not been previously evaluated in osteoblast-like cells and 
would be a potentially novel addition to the current study.  Alterations in iron-regulated 
gene and protein expression with acute excessive iron treatment are another aspect that 
would provide more insight into time-dependent effects.  The acute excessive iron 
treatment effects on key iron-regulated gene and protein expression of transferrin 
receptor, ferritin light chain, and ferritin heavy chain with osteoblast-like cells isolated 
from fetal rat calvaria are currently being evaluated in our lab.  
Links between oxidative stress and the suppression of osteoblast development 
have been reported by Bai et al. (2004) and Arai et al. (2007).  These studies reported that 
increased oxidative stress in osteoblasts induced by H2O2 suppressed the key osteogenic 
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marker gene expression of alkaline phosphatase, bone sialoprotein, type I collagen, and 
Runx2.  Although animal study findings have shown a relationship between iron 
overload, oxidative stress, and decreased BMD, further analyses of oxidative stress in 
relation to iron overload and osteoblast development in vitro is still needed.  Further in 
vitro analysis might be conducted by evaluating the effects of iron overload on oxidative 
stress markers.  Glutathione peroxidase is one example of an antioxidant that is released 
from osteoblasts (Isomura et al. 2004).  Alkaline phosphatase and bone sialoprotein gene 
expression were also reported in the current study to be suppressed with excessive iron 
treatment, but type I collagen and Runx2 were not evaluated.  An analysis of these genes 
in relation to excessive iron and osteoblasts would be a potential next step in evaluating 
alterations in other osteogenic markers.  
Cellular death by apoptosis or necrosis may also be induced in response to iron 
overload.  An evaluation of acute apoptotic effects of iron overload on osteoblast-like 
cells isolated from fetal rat calvaria is currently underway.  Cell death via apoptosis can 
be initiated by a multitude of processes, but two specific pathways are through the 
intrinsic pathway or mitochondria’s release of cytochrome-c and the extrinsic pathway or 
by “death” receptors (Ueda et al. 2002).  Studies in vitro have reported that iron overload 
induces apoptosis predominately by the intrinsic pathway (Doulias et al. 2003, Rauen et 
al. 2004).  Cytochrome-c release from the mitochondria is one initiator of caspases, 
specifically caspase-3 and caspase-9 (Ueda et al. 2002).  These active and inactive forms 
of these proteins are currently being evaluated in our lab, along with other early 
indicators of apoptosis such as DNA fragmentation and phosphatidyl serine relocation.  
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The extrinsic pathway and necrosis are other potential directions that could be further 
analyzed.  The extrinsic pathway is initiated through the Fas death domain protein and in 
turn activates caspases 8 and 10.  Caspase-8 can initiate the release of cytochrome-c by 
activating Bid which is part of the pro-apoptotic Bcl-2 family (Ghobrial et al. 2005).  
Reactive oxygen species have been reported to inhibit caspase-9 and cause necrosis 
instead of apoptosis (Ueda et al. 2002).  An assessment of elevated cellular death could 
further support potential mechanisms correlating iron overload to the suppression of 
osteoblast development.     
There are inherent limitations to in vitro studies, including cell culture conditions. 
First, extending the length of cell culture past day 21 may have provided insight into the 
nature of the effects of iron.  The suppression of osteoblast function and maturation might 
be “rescued” after this time frame if the iron-related effects were due to a delay rather 
than a suppression of osteoblast maturation.  The detachment of cells from the plate and 
overgrowth of cell layers at the end of culture (~D20-21) made this analysis difficult.  
Second, iron overload may also interfere with mineralization per se of the multilayered 
nodules, used as an in vitro indicator of osteoblast function.  In iron overloaded cells, 
multilayering was evident but little was mineralized.  Thus, a separate quantification of 
unmineralized nodules would be informative. Previous studies have reported that iron 
overload in humans does not affect serum calcium levels (Wardle et al. 1969, Salama et 
al. 2006).  However, animal studies have reported that urinary calcium levels increase 
with dietary iron overload (Matsushima et al. 2001).  Due to the major role of calcium in 
bone mineralization, analysis of calcium levels may also be informative.
 
 
47 
 
REFERENCES 
 
 
 
1. Anelopoulos NG, Goula AK, Papanikolaou G, Tolis G.  Osteopososis in HFE2 
juvenile hemochromatosis.  A case report and review of literature.  Osteoporos Int. 
2006;17:150-5. 
2. Arai M, Shibata Y, Pugdee K, Abiko Y, Ogata Y.  Effects of reactive oxygen species 
(ROS) on antioxidant system and osteoblastic differentiation in MC3T3-E1 cells.  
IUBMB Life.  2007;59(1):27-33. 
3. Arredondo M, Nunez MT.  Iron and copper metabolism.  Mol Aspects Med. 
2005;26:313-27. 
4. Aubin JE.  Advances in the osteoblast lineage.  Biochem Cell Biol. 1998;76(6):899-
910.  
5. Bacon B.  Hemochromatosis: Diagnosis and management.  Gastroenterology.  
2001;120:718-25.  Review. 
6. Bai X, Lu D, Bai J, Zheng H, Ke Z, Li X et al.  Oxidative stress inhibits osteoblastic 
differentiation of bone cells by ERK and NF-kappaB.  Biochem Biophys Res 
Commun. 2004;314(1):197-207. 
7. Basu S, Michaelsson K, Olofsson H, Johansson S, Melhus H.  Association between 
oxidative stress and bone mineral density.  Biochem Biophys Res Commun. 
2001;288(1):275-9. 
 
 
 
48 
 
8. Beard JL.  Iron biology in immune function, muscle metabolism and neuronal 
functioning.  J Nutr. 2001;131:568S-80S.  
9. Beauchamp JR, Woodman PG.  Regulation of transferrin receptor recycling by 
protein phosphorylation.  Biochem J. 1994;303(Pt 2):647-55. 
10. Besarab A, Frinak S, Yee J.  An indistinct balance: The safety and efficacy of 
parenteral iron therapy.  J Am Soc Nephrol. 1999;10:2029-43. 
11. Blanck HM, Cogswell ME, Gillespie C, Reyes M.  Iron supplement use and iron 
status among US adults: results from the third National Health and Nutrition 
Examination Survey.  Am J Clin Nutr. 2005;82(5):1024-31. 
12. Cable EE, Connor JR, Isom HC.  Accumulation of iron by primary rat hepatocytes in 
long-term culture: changes in nuclear shape mediated by non-transferrin-bound forms 
of iron.  Am J Pathol.  1998;152(3):781-92.  
13. Cairo G, Recalcati S, Pietrangelo A, Minotti G.  The iron regulatory proteins: targets 
and modulators of free radical reactions and oxidative damage.  Free Radic Biol Med. 
2002;32(12):1237-43. Review. 
14. Chiancone E, Ceci P, Ilari A, Ribacchi F, Stefanini S. Iron and proteins for iron 
storage and detoxification. Biometals. 2004;17(3):197-202. Review. 
15. Crichton RR, Wilmet S, Legssyer R, Ward R.  Molecular and cellular mechanisms of 
iron homeostasis and toxicity in mammalian cells.  J Inorg Biochem. 2002;91:9-18. 
16. Cohen MM Jr.  The new bone biology: pathologic, molecular, and clinical correlates. 
Am J Med Genet A. 2006;140(23):2646-706.  Review.   
 
49 
 
17. Davis RJ, Corvera S, Czech MP.  Insulin stimulates cellular iron uptake and causes 
the redistribution of intracellular transferrin receptors to the plasma membrane.  J 
Biol Chem. 1986;261(19):8708-11. 
18. Davis RJ, Czech MP.  Regulation of transferrin receptor expression at the cell surface 
by insulin-like growth factors, epidermal growth factor and platelet-derived growth 
factor.  EMBO J. 1986;5(4):653-8. 
19. Davis RJ, Faucher M, Racaniello LK, Carruthers A, Czech MP.  Insulin-like growth 
factor I and epidermal growth factor regulate the expression of transferrin receptors at 
the cell surface by distinct mechanisms.  J Biol Chem. 1987;262(27):13126-34. 
20. De Vernejoul MC, Pointillart A, Golenzer CC, Morieux C, Bielakoff J, Modrowski 
D, et al.  Effects of iron overload on bone remodeling in pigs.  Am J Pathol. 
1984;116(3):377-84.  
21. Diamond T, Stiel D, Posen S.  Osteoporosis in hemochromatosis: iron excess, 
gonadal deficiency, or other factors?  Ann Intern Med. 1989:110;430-6. 
22. Domrongkitchaiporn S, Sirikulchayanonta V, Angchaisuksiri P, Stitchantrakul W, 
Kanokkantapong C, Rajatanavin R.  Abnormalities in bone mineral density and bone 
histology in thalassemia.  J Bone Miner Res. 2003;18(9):1682-8.  
23. Doulias PT, Christoforidis S, Brunk UT, Galaris D.  Endosomal and lysosomal effects 
of desferrioxamine: protection of HeLa cells from hydrogen peroxide-induced DNA 
damage and induction of cell-cycle arrest.  Free Radical Biol Med. 2003;35:719-28. 
24. Eisenstein RS.  Iron regulatory proteins and the molecular control of mammalian iron 
metabolism.  Annu Rev Nutr. 2000;20:627-62. Review. 
 
50 
 
25. Erikson KM, Aschner M.  Increased manganese uptake by primary astrocyte cultures 
with altered iron status is mediated primarily by divalent metal transporter.  
Neurotoxicology 2006:27;125-30.   
26. Fisher AE, Naughton DP.  Iron supplements: the quick fix with long-term 
consequences.  Nutr J. 2004;3:2. 
27. Gentili C, Doliana R, Bet P, Campanile G, Colombatti A, Cancedda FD, et al.  
Ovotransferrin and ovotransferrin receptor expression during chondrogenesis and 
endochondral bone formation in developing chick embryo.  J Cell Biol. 1994;124(4): 
579-88. 
28. Greene BT, Thorburn J, Willingham MC, Thorburn A, Planalp RP, Brechbiel MW et 
al.  Activation of caspase pathways during iron chelator-mediated apoptosis.  J Biol 
Chem.  2002;277:25568-75. 
29. Guggenbuhl P, Deugnier Y, Boisdet JF, Rolland Y, Perdriger A, Pawlotsky Y, et al.  
Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. 
Osteoporos Int. 2005;16(12):1809-14.   
30. Hall SL, Greendale GA.  The relation of dietary vitamin C intake to bone mineral 
density: results from the PEPI study.  Calcif Tissue Int. 1998;63(3):183-9. 
31. Hampton MB, Orrenius S.  Redox regulation of apoptotic cell death.  Biofactors 
1998;8:1-5.  Review. 
32. Hinoi E, Fujimori S, Wang L, Hojo H, Uno K, Yoneda Y.  Nrf2 negatively regulates 
osteoblast differentiation via interfering with Runx2-dependent transcriptional 
activation.  J Biol Chem. 2006;281(26):18015-24. Hoepken HH, Korten T, Robinson 
 
51 
 
SR, Dringen R.  Iron accumulation, iron-mediated toxicity and altered levels of 
ferritin and transferrin receptor in cultured astrocytes during incubation with ferric 
ammonium citrate.  J Neurochem. 2002;88(5):1194-202.  
33. Iancu TC, Shiloh H, Link G, Baugminger ER, Pinson A, Hershko C.  Ultrastructural 
pathology of iron-loaded rat myocardial cells in culture.  Br J Exp Pathol. 
1987;68(1):53-65.  
34. Ilich JZ, Kerstetter JE.  Nutrition in bone health revisited: a story beyond calcium.  J 
Am Coll Nutr. 2000;19(6):715-37. Review. 
35. Isomura H, Fujie K, Shibata K, Inoue N, Iizuka T, Takebe G, et al.  Bone metabolism 
and oxidative stress in postmenopausal rats with iron overload.  Toxicology 
2004:197;93-100. 
36. Jacobs A, Miller F, Worwood M, Beamish MR, Wardrop CA.  Ferritin in the serum 
of normal subjects and patients with iron deficiency and iron overload.  Br Med J. 
1972;4(5834):206-8. 
37. Jehn M, Clark J, Guallar E.  Serum ferritin and risk of the metabolic syndrome in 
U.S. adults.  Diabetes Care 2004;27:2422-28. 
38. Jing SQ, Spencer T, Miller K, Hopkins C, Trowbridge IS.  Role of the human 
transferrin receptor cytoplasmic domain in endocytosis: localization of a specific 
signal sequence for internalization. 
J Cell Biol. 1990 Feb;110(2):283-94. 
39. Johnson MA, Fischer JG, Bowman BA, Gunter EW.  Iron nutriture in elderly 
individuals.  FASEB J. 1994 Jun;8(9):609-21. Review. Kasai K, Hori MT, Goodman 
 
52 
 
WG.  Characterization of the transferrin receptor in UMR-106-01 osteoblast-like 
cells.  Endocrinology 1990;126(3):1742-9.   
40. Kurz T, Leake A, Zglinicki T, Brunk U.  Relocalized redox-active iron is an 
important mediator of oxidative-stress-induced DNA damage.  Biochem. J. 
2004;378:1039-45. 
41. Leveille SG, LaCroix AZ, Koepsell TD, Beresford SA, Van Belle G, Buchner DM et 
al.  Dietary vitamin C and bone mineral density in postmenopausal women in 
Washington State, USA.  J Epidemiol Community Health. 1997;51(5):479-85. 
42. Liu G, Men P, Kenner GH, Miller S.  Age-associated iron accumulation in bone: 
Implications for postmenopausal osteoporosis and a new target for prevention and 
treatment by chelation.  Biometals 2006;19(3):245-51. 
43. Liu JM, Hankinson SE, Stampfer MJ, Rifai N, Willett WC, Ma J.  Iron supplement 
use and iron status among US adults: results from the third National Health and 
Nutrition Examination Survey.  Am J Clin Nutr. 2003;82(5):1024-31. 
44. Lu JP, Hayashi K, Okada S, Awai M.  Tranferrin receptors and selective iron 
deposition in pancreatic B cells of iron-overloaded rats.  Acta Pathol Jpn.  
1991;41(9):647-52. 
45. Maggio D, Barabani M, Pierandrei M, Polidori MC, Catani M, Mecocci P et al.  
Marked decrease in plasma antioxidants in aged osteoporotic women: results of a 
cross-sectional study.  J Clin Endocrinol Metab. 2003;88(4):1523-7. 
46. Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A., Karnsombat P, 
Choubtum L, Sriphrapradang A, et al.  Bone histomorphometry in children and 
 
53 
 
adolescents with β-Thalassemia disease: iron-associated focal osteomalacia.  J Clin 
Endocrinol Metab. 2003;88(8):3966-72. 
47. Mainous AG 3
rd
, Wells B, Carek PJ, Gill JM, Geesey ME.  The mortality risk of 
elevated serum transferrin saturation and consumption of dietary iron.  Ann Fam 
Med. 2004;2(2):139-44. 
48. Malecki EA, Buhl KM, Beard JL, Jacobs CR, Connor JR, Donahue HJ.  Bone 
structural and mechanical properties are affected by hypotransferrinemia but not by 
iron deficiency in mice.  J Bone Miner Res. 2000;15(2):271-7.  
49. Matsushima S, Hoshimoto M, Torii M, Ozaki K, Narama I.  Iron lactate-induced 
osteopenia in male Sprague-dawley rats.  Toxicol Pathol.  2001;29:623-9. 
50. Maurer J, Harris MM, Stanford VA, Lohman TG, Cussler E., Going SB et al.  Dietary 
iron positively influences bone mineral density in postmenopausal women on 
hormone replacement therapy.  J Nutr. 2005;135(4):863-9.  
51. Medeiros DM, Plattner A, Jennings D, Stoecker B.  Bone morphology, strength and 
density are compromised in iron-deficient rats and exacerbated by calcium restriction. 
J Nutr. 2002;132(10):3135-41. 
52. Medeiros DM, Stoecker B, Plattner A, Jennings D, Haub M.  Iron deficiency 
negatively affects vertebrae and femurs of rats independently of energy intake and 
body weight.  J Nutr. 2004;134:3061-7.  
53. Milman N, Koefoed P, Pedersen P, Nielsen FC, Eiberg H.  Iron status in Danish 
women, 1984-1994: a cohort comparison of changes in iron stores and the prevalence 
of iron deficiency and iron overload.  Eur J Haematol. 2003 Jul;71(1):51-61. 
 
54 
 
54. Parkes JG, Randell EW, Olivieri NF, Templeton DM.  Modulation by iron loading 
and chelation of the uptake of non-transferrin-bound iron by human liver cells.  
Biochim Biophys Acta. 1993;1243(3):373-80.  
55. Pietrangelo A, Rocchi E, Schiaffonati L, Ventura E, Cairo G.  Liver gene expression 
during chronic dietary iron overload in rats.  Hepatology.  1990;11(5):798-804.  
56. Pietrangelo A, Rocci E, Ferrari A, Ventura E, Cairo G.  Regulation of hepatic 
transferrin, transferrin receptor and ferritin genes in human siderosis.  Hepatology.  
1991;14(6):1083-9.  
57. Pietrangelo A, Rocci E, Casalgrandi G, Rigo G, Ferrari A, Perini M et al.  Regulation 
of transferrin, transferrin receptor, and ferritin genes in human duodenum.  
Gastroenterology.  1992;102(3):802-9.  
58. Puntarulo S.  Iron, oxidative stress and human health.  Mol Aspects Med. 2005;26(4-
5):235-44.  Review. 
59. Rauen U, Petrat F, Sustmann F, Groot H.  Iron-induced mitochondrial permeability 
transition in cultured hepatocytes.  J Hepatol. 2004;40:607-15. 
60. Salama OS, Al-Tonbary YA, Shahin RA, Eldeen OA.  Unbalanced bone turnover in 
children with beta-thalassemia.  Hematology. 2006;11(3):197-202.  
61. Sheth S, Brittenham GM.  Genetic disorders affecting proteins of iron metabolism: 
clinical implications.  Ann Intern Med. 2000;51:443-64. 
62. Siah CW, Ombiga J, Adams L, Trinder D, Olynyk JK.  Normal iron metabolism and 
the pathophysiology of iron overload disorders.  Clin Biochem Rev. 2006 
Feb;27(1):5-16.   
 
55 
 
63. Siggelkow S, Kossev A, Schubert M, Kappels HH, Wold W, Dengler R.  
Development of the osteoblast phenotype in primary human osteoblasts in culture: 
comparison with rat calvarial cells in osteoblast differentiation.  J Cell Biochem. 
1999;75(1):22-35.   
64. Simunek T, Boer C, Bouwman RA, Vlasblom R, Versteilen AM, Sterba M, et al. 
SIH--a novel lipophilic iron chelator--protects H9c2 cardiomyoblasts from oxidative 
stress-induced mitochondrial injury and cell death.  J Mol Cell Cardiol. 
2005;39(2):345-54.  
65. Sinigaglia L, Fargion S, Francanzani AL, Binelli L, Battafarano N, Varenna M, et al.  
Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron 
overload.  J Rheumatol. 1997;24(9):1809-13.  
66. Spanner M, Weber K, Lanske B, Ihbe A, Siggelkow H, Schutze H, et al.  The iron-
binding protein ferritin is expressed in cells of the osteoblastic lineage in vitro and in 
vivo.  Bone 1995;17(2):161-5. 
67. Tenopoulou M, Douglias PT, Barboutie A, Brunk U, Galaris D.  Role of 
compartmentalized redo-active iron in hydrogen peroxide-induced DNA damage and 
apoptosis.  Biochem J. 2005;387:703-10. 
68. Van Driel IR, Goding JW.  Heterogeneous glycosylation of murine transferrin 
receptor subunits.  Eur J Biochem. 1985;149(3):543-8. 
69. Ueda S, Masutani H, Nakamura H, Tanaka T, Ueno M, Yodoi J.  Redox control of 
cell death.  Antioxid Redox Signal. 2002;4(3):405-14.  Review. 
 
56 
 
70. Voskaridou E, Terpos E.  New insights into the pathophysiology and management of 
osteoporosis in patients with beta thalassaemia. Br J Haematol. 2004;127(2):127-39. 
Review.   
71. Walter PB, Knutson MD, Paler-Martinez A, Lee S, Xu Y, Viteri FE, Ames BN.  Iron 
deficiency and iron excess damage mitochondria and mitochondrial DNA in rats.  
Proc Natl Acad Sci U S A. 2002;99(4):2264-9. 
72. Weinberg ED.  Iron loading: a risk factor for osteoporosis.  Biometals 
2006;19(6):633-5. 
73. Yang B, Hoe MH, Black P, Hunt RC.  Role of oligosaccharides in the processing and 
function of human transferrin receptors. Effect of the loss of the three N-glycosyl 
oligosaccharides individually or together.  J Biol Chem. 1993;268(10):7435-41. 
 
 
 
57 
 
APPENDIX. Iron Concentration. 
 
 
 
Table 2 :  Media and reagent iron concentration determined by Graphite Furnace Atomic 
Absorption Spectrometry.   
 
Media Plus Treatment Doses* µmol/L Components of Media Solution µmol/L 
0 µM (Control) 0.0031 α – Modified Eagles Medium 0.0003 
1 µM 0.0041 Fetal Bovine Serum
1
 0.0315 
2 µM 0.0049 Dexamethasone 0.0006 
3 µM 0.0057 Phosphate Buffer Saline 0.0002 
4 µM 0.0067 Nitric Acid 0.0002 
5 µM 0.0072 Deionized Water 0.0000 
  β – Glycerol Phosphate 0.0017 
  Antibiotics 0.0003 
 
1 
Manufacturer value:  0.0291 µmol/L, * Media components listed in right column 
 
 
